Research advances in lean nonalcoholic fatty liver disease

Yujuan ZHANG; Xiqiao ZHOU

doi:10.3969/j.issn.1001-5256.2023.12.024

Volume 39 Issue 12

Dec. 2023

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(12): 2914-2919

PDF( 593 KB)

Research advances in lean nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2023.12.024

Yujuan ZHANG¹,
Xiqiao ZHOU^{2
,
,
,}

1.
The First Clinical Medical College of Nanjing University of Chinese Medicine，Nanjing 210000，China
2.
Department of Endocrinology，The Affiliated Hospital of Nanjing University of Chinese Medicine，Nanjing 210000，China

Research funding:

Project of Administration of Traditional Chinese Medicine of Jiangsu Province of China (ZT202105)

More Information

Corresponding author: ZHOU Xiqiao， zhouxiqiao@njucm.edu.cn （ORCID： 0000-0003-3122-3904）
Received Date: 2023-03-29
Accepted Date: 2023-05-15
Published Date: 2023-12-12

Abstract

Abstract

Nonalcoholic fatty liver disease （NAFLD） is currently the main cause of chronic liver disease worldwide， and it can progress to hepatitis， liver fibrosis， liver cirrhosis， and even hepatocellular carcinoma. Although obesity plays a key role in the development of NAFLD， more and more studies have confirmed that NAFLD still exists in lean individuals， and lean NAFLD is associated with an increased risk of death and accelerated disease progression. Therefore， lean NAFLD also deserves careful evaluation and follow-up； however， we still know little about the pathophysiological mechanism of lean NAFLD. This article reviews the etiology， diagnosis， treatment， and prognosis of lean NAFLD.
- Nonalcoholic Fatty Liver Disease,
- Somatotypes,
- Diagnosis,
- Therapeutics,
- Risk Factors

FullText(HTML)

References(43)

References

[1]	YE Q, ZOU BY, YEO YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: A systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2020, 5( 8): 739- 752. DOI: 10.1016/S2468-1253(20)30077-7.
[2]	WEINBERG EM, TRINH HN, FIRPI RJ, et al. Lean Americans with nonalcoholic fatty liver disease have lower rates of cirrhosis and comorbid diseases[J]. Clin Gastroenterol Hepatol, 2021, 19( 5): 996- 1008.e6. DOI: 10.1016/j.cgh.2020.06.066.
[3]	ZOU B, YEO YH, NGUYEN VH, et al. Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999-2016[J]. J Intern Med, 2020, 288( 1): 139- 151. DOI: 10.1111/joim.13069.
[4]	NIRIELLA MA, KASTURIRATNE A, PATHMESWARAN A, et al. Lean non-alcoholic fatty liver disease(lean NAFLD): Characteristics, metabolic outcomes and risk factors from a 7-year prospective, community cohort study from Sri Lanka[J]. Hepatol Int, 2019, 13( 3): 314- 322. DOI: 10.1007/s12072-018-9916-4.
[5]	ZENG J, YANG RX, SUN C, et al. Prevalence, clinical characteristics, risk factors, and indicators for lean Chinese adults with nonalcoholic fatty liver disease[J]. World J Gastroenterol, 2020, 26( 15): 1792- 1804. DOI: 10.3748/wjg.v26.i15.1792.
[6]	NAVARROZA AMC, WONG SN. Comparison of clinical and metabolic profiles of lean versus non-lean nonalcoholic fatty liver disease[J]. Indian J Gastroenterol, 2021, 40( 4): 380- 388. DOI: 10.1007/s12664-021-01184-6.
[7]	NADERIAN M, KOLAHDOOZAN S, SHARIFI AS, et al. Assessment of lean patients with non-alcoholic fatty liver disease in a middle income country; prevalence and its association with metabolic disorders: A cross-sectional study[J]. Arch Iran Med, 2017, 20( 4): 211- 217.
[8]	YOUNES R, GOVAERE O, PETTA S, et al. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: Time for reappraisal of BMI-driven approach?[J]. Gut, 2022, 71( 2): 382- 390. DOI: 10.1136/gutjnl-2020-322564.
[9]	SHIDA T, OSHIDA N, SUZUKI H, et al. Clinical and anthropometric characteristics of non-obese non-alcoholic fatty liver disease subjects in Japan[J]. Hepatol Res, 2020, 50( 9): 1032- 1046. DOI: 10.1111/hepr.13543.
[10]	FENG RN, DU SS, WANG C, et al. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population[J]. World J Gastroenterol, 2014, 20( 47): 17932- 17940. DOI: 10.3748/wjg.v20.i47.17932.
[11]	BYEON JH, KANG MK, KIM MC. Association of low skeletal muscle mass with the phenotype of lean non-alcoholic fatty liver disease[J]. Healthcare, 2022, 10( 5): 850. DOI: 10.3390/healthcare10050850.
[12]	ZHANG XX, HE ZY, SI QY, et al. The association of sarcopenia and visceral obesity with lean nonalcoholic fatty liver disease in Chinese patients with type 2 diabetes mellitus[J]. J Diabetes Res, 2022, 2022: 1- 8. DOI: 10.1155/2022/2229139.
[13]	ZHU X, HUANG Q, MA S, et al. Presence of sarcopenia identifies a special group of lean NAFLD in middle-aged and older people[J]. Hepatol Int, 2023, 17( 2): 313- 325. DOI: 10.1007/s12072-022-10439-z.
[14]	CHO Y, CHANG Y, RYU S, et al. Skeletal muscle mass to visceral fat area ratio as a predictor of NAFLD in lean and overweight men and women with effect modification by sex[J]. Hepatol Commun, 2022, 6( 9): 2238- 2252. DOI: 10.1002/hep4.1975.
[15]	GAO N, DENG J, WANG J, et al. The prevalence, comorbidities, influencing factors, and identifying factors of non-obese fatty liver disease[J]. Front Med(Lausanne), 2022, 9: 1038475. DOI: 10.3389/fmed.2022.1038475.
[16]	RASTOGI A, RATH I, VARADARAJAN A, et al. Non-alcoholic fatty liver disease(NAFLD) in lean individuals-Single centre large cohort clinicopathologic and immunophenotypic study[J]. Pathol Res Pract, 2022, 238: 154112. DOI: 10.1016/j.prp.2022.154112.
[17]	AKYUZ U, YESIL A, YILMAZ Y. Characterization of lean patients with nonalcoholic fatty liver disease: Potential role of high hemoglobin levels[J]. Scand J Gastroenterol, 2015, 50( 3): 341- 346. DOI: 10.3109/00365521.2014.983160.
[18]	CHEN F, ESMAILI S, ROGERS GB, et al. Lean NAFLD: A distinct entity shaped by differential metabolic adaptation[J]. Hepatology, 2020, 71( 4): 1213- 1227. DOI: 10.1002/hep.30908.
[19]	HU PF, ZENG X, ZOU ZY, et al. The presence of NAFLD in nonobese subjects increased the risk of metabolic abnormalities than obese subjects without NAFLD: A population-based cross-sectional study[J]. Hepatobiliary Surg Nutr, 2021, 10( 6): 811- 824. DOI: 10.21037/hbsn-20-263.
[20]	WANG QY, YOU H, OU XJ, et al. Non-obese histologically confirmed NASH patients with abnormal liver biochemistry have more advanced fibrosis[J]. Hepatol Int, 2019, 13( 6): 766- 776. DOI: 10.1007/s12072-019-09982-z.
[21]	LI YF, CHEN YZ, TIAN X, et al. Comparison of clinical characteristics between obese and non-obese patients with nonalcoholic fatty liver disease(NAFLD)[J]. Diabetes Metab Syndr Obes, 2021, 14: 2029- 2039. DOI: 10.2147/dmso.s304634.
[22]	KWAK JH, JUN DW, LEE SM, et al. Lifestyle predictors of obese and non-obese patients with nonalcoholic fatty liver disease: A cross-sectional study[J]. Clin Nutr, 2018, 37( 5): 1550- 1557. DOI: 10.1016/j.clnu.2017.08.018.
[23]	LI CL, GUO PP, OKEKUNLE AP, et al. Lean non-alcoholic fatty liver disease patients had comparable total caloric, carbohydrate, protein, fat, iron, sleep duration and overtime work as obese non-alcoholic fatty liver disease patients[J]. J Gastroenterol Hepatol, 2019, 34( 1): 256- 262. DOI: 10.1111/jgh.14360.
[24]	LIN H, WONG GL, WHATLING C, et al. Association of genetic variations with NAFLD in lean individuals[J]. Liver Int, 2022, 42( 1): 149- 160. DOI: 10.1111/liv.15078.
[25]	SOOKOIAN S, PIROLA CJ. Genetic predisposition in nonalcoholic fatty liver disease[J]. Clin Mol Hepatol, 2017, 23( 1): 1- 12. DOI: 10.3350/cmh.2016.0109.
[26]	IWAKI M, KESSOKU T, OZAKI A, et al. Gut microbiota composition associated with hepatic fibrosis in non-obese patients with non-alcoholic fatty liver disease[J]. J Gastroenterol Hepatol, 2021, 36( 8): 2275- 2284. DOI: 10.1111/jgh.15487.
[27]	IINO C, ENDO T, IINO K, et al. Reduced equol production and gut microbiota features in men with lean nonalcoholic fatty liver disease[J]. Am J Mens Health, 2022, 16( 4): 15579883221115598. DOI: 10.1177/15579883221115598.
[28]	YANG YJ, YANG EJ, PARK K, et al. Association between blood mercury levels and non-alcoholic fatty liver disease in non-obese populations: The Korean national environmental health survey(KoNEHS) 2012-2014[J]. Int J Environ Res Public Heath, 2021, 18( 12): 6412. DOI: 10.3390/ijerph18126412.
[29]	LONG MT, NOUREDDIN M, LIM JK. AGA clinical practice update: Diagnosis and management of nonalcoholic fatty liver disease in lean individuals: Expert review[J]. Gastroenterology, 2022, 163( 3): 764- 774.e1. DOI: 10.1053/j.gastro.2022.06.023.
[30]	LI K, LI J, CHENG X, et al. Association between the atherogenic index of plasma and new-onset non-alcoholic fatty liver disease in non-obese participants[J]. Front Endocrinol(Lausanne), 2022, 13: 969783. DOI: 10.3389/fendo.2022.969783.
[31]	ZOU Y, ZHONG L, HU C, et al. LDL/HDL cholesterol ratio is associated with new-onset NAFLD in Chinese non-obese people with normal lipids: A 5-year longitudinal cohort study[J]. Lipids Health Dis, 2021, 20( 1): 28. DOI: 10.1186/s12944-021-01457-1.
[32]	LI Q, HAN Y, HU H, et al. Gamma-glutamyl transferase to high-density lipoprotein cholesterol ratio has a non-linear association with non-alcoholic fatty liver disease: A secondary prospective cohort study in non-obese Chinese adults[J]. Front Med(Lausanne), 2022, 9: 995749. DOI: 10.3389/fmed.2022.995749.
[33]	XIE QY, LU S, KUANG MB, et al. Assessing the longitudinal association between the GGT/HDL-C ratio and NAFLD: A cohort study in a non-obese Chinese population[J]. BMC Gastroenterol, 2022, 22( 1): 500. DOI: 10.1186/s12876-022-02598-y.
[34]	CHAN WK. Comparison between obese and non-obese nonalcoholic fatty liver disease[J]. Clin Mol Hepatol, 2023, 29( Suppl): S58- S67. DOI: 10.3350/cmh.2022.0350.
[35]	LI C, GUO P, ZHANG R, et al. Both WHR and FLI as Better Algorithms for Both Lean and Overweight/Obese NAFLD in a Chinese Population. J Clin Gastroenterol. 2019; 53( 6): e253- e260. DOI: 10.1097/MCG.0000000000001089.
[36]	ZHANG XL, WANG TY, TARGHER G, et al. Lifestyle interventions for non-obese patients both with, and at risk, of non-alcoholic fatty liver disease[J]. Diabetes Metab J, 2022, 46( 3): 391- 401. DOI: 10.4093/dmj.2022.0048.
[37]	WONG VWS, WONG GLH, CHAN RSM, et al. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease[J]. J Hepatol, 2018, 69( 6): 1349- 1356. DOI: 10.1016/j.jhep.2018.08.011.
[38]	CIGROVSKI BERKOVIC M, BILIC-CURCIC I, MRZLJAK A, et al. NAFLD and physical exercise: Ready, steady, go![J]. Front Nutr, 2021, 8: 734859. DOI: 10.3389/fnut.2021.734859.
[39]	ABDELMONEIM D, EL-ADL M, EL-SAYED G, et al. Protective effect of fenofibrate against high-fat-high-fructose diet induced non-obese NAFLD in rats[J]. Fundam Clin Pharmacol, 2021, 35( 2): 379- 388. DOI: 10.1111/fcp.12597.
[40]	KIM Y, HAN E, LEE JS, et al. Cardiovascular risk is elevated in lean subjects with nonalcoholic fatty liver disease[J]. Gut Liver, 2022, 16( 2): 290- 299. DOI: 10.5009/gnl210084.
[41]	CHEN N, ZHOU JQ, WANG K, et al. Non-obese or lean non-alcoholic fatty liver disease was associated with increased risk of cancer in patients with type 2 diabetes mellitus[J]. BMJ Open Diabetes Res Care, 2023, 11( 1): e003066. DOI: 10.1136/bmjdrc-2022-003066.
[42]	KUMAR R, MOHAN S. Non-alcoholic fatty liver disease in lean subjects: Characteristics and implications[J]. J Clin Transl Hepatol, 2017, 5( 3): 216- 223. DOI: 10.14218/JCTH.2016.00068.
[43]	NABI O, LAPIDUS N, BOURSIER J, et al. Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes(NASH-CO Study)[J]. Hepatology, 2023, 78( 1): 272- 283. DOI: 10.1097/hep.0000000000000329.

Relative Articles

[1]	Shuaixia FENG, Ying XU, Han HAN. Role and potential significance of peroxisome proliferator-activated receptors in liver diseases[J]. Journal of Clinical Hepatology, 2023, 39(7): 1747-1753. doi: 10.3969/j.issn.1001-5256.2023.07.034
[2]	Jiahe ZHAO, Xinyu MA, Jingya XU, Tingting DUAN, Chunlei ZHANG, Baolong LI. Research advances in related factors for autophagy in the regulation of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2021, 37(7): 1713-1717. doi: 10.3969/j.issn.1001-5256.2021.07.050
[3]	Li WenMi, Wang Nan, Bian Qian, Huang Qian, Li JingTao, Wei HaiLiang, Yan ShuGuang. Role of liver X receptor in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(10): 2349-2352. doi: 10.3969/j.issn.1001-5256.2020.10.041
[4]	Chen YiYan, Lu Yan. Application of nuclear receptor in pathogenesis research and drug development for nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(6): 1221-1223. doi: 10.3969/j.issn.1001-5256.2020.06.006
[5]	Ren Shan, Du XiaoFei, Huang YunLi, Huang ChunYang, Zhang XiaoDan, Dan Jing, Chen XinYue. Serum interferon-gamma-induced protein-10 level and gene polymorphism in patients with drug-induced liver injury accompanied by autoimmune phenomena[J]. Journal of Clinical Hepatology, 2020, 36(3): 602-607. doi: 10.3969/j.issn.1001-5256.2020.03.026
[6]	A RuHan, Jia HaiYan, Ding YanHua, Niu JunQi. Research advances in nonalcoholic fatty liver disease in lean individuals[J]. Journal of Clinical Hepatology, 2020, 36(5): 1154-1159. doi: 10.3969/j.issn.1001-5256.2020.05.046
[7]	Chu PeiLing, Wang Qi, Guo XiaoQing, Liu JinChun. Association between chemokines and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2019, 35(7): 1626-1628. doi: 10.3969/j.issn.1001-5256.2019.07.044
[8]	Ou WeiJie, Lin YeHong, Zhou Qing, Shang TianYu, Lin Su, Zhu YueYong. Association of vitamin D-related gene polymorphisms with hepatitis B virus-related acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2019, 35(6): 1308-1312. doi: 10.3969/j.issn.1001-5256.2019.06.025
[9]	Liu Qun, Luan GuiPing, Gao Hui, Zhao BenTian, Du ShuiXian, Liu ShouSheng, Xin YongNing. Association of TRIB1 rs2954029 single nucleotide polymorphism with the risk of nonalcoholic fatty liver disease and coronary heart disease[J]. Journal of Clinical Hepatology, 2019, 35(6): 1330-1336. doi: 10.3969/j.issn.1001-5256.2019.06.030
[10]	Zhou Fan, Peng JunWei, Fan FuGang, Jiang YuanYe, Cao Qin. Interrelation between autophagy and oxidative stress in pathogenesis of nonalcoholic fatty liver[J]. Journal of Clinical Hepatology, 2018, 34(8): 1805-1808. doi: 10.3969/j.issn.1001-5256.2018.08.048
[12]	Liao SongLing, Liu ShouSheng, Wang Cong, Chen LiZhen, Xin YongNing, Xuan ShiYing. Association between MBOAT7 rs641738 polymorphism and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2018, 34(10): 2169-2174. doi: 10.3969/j.issn.1001-5256.2018.10.021
[13]	Yue HaiYan, Liu ShouSheng, Wang Cong, Gu JiuLian, Xin YongNing, Xuan ShiYing. Association between single nucleotide polymorphism of low-density lipoprotein receptor and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2018, 34(9): 1929-1935. doi: 10.3969/j.issn.1001-5256.2018.09.021
[14]	Zhang Hua, He DeHua, Li GuiZhong. Association between single nucleotide polymorphism of microRNA-146a and recurrence after liver cancer surgery[J]. Journal of Clinical Hepatology, 2016, 32(5): 904-907. doi: 10.3969/j.issn.1001-5256.2016.05.018
[15]	Liu Yang, Jiang Man, Chen LiZhen, Du ShuiXian, Xin YongNing, Xuan ShiYing. Association between AGTR1 gene polymorphism and risk of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2015, 31(7): 1082-1087. doi: 10.3969/j.issn.1001-5256.2015.07.020
[16]	Xu Xin, Jiang Man, Li JiangWen, Dong QuanYong, Lin ZhongHua, Chu LeiLei, Xin YongNing, Xuan ShiYing. Association between PPARγ gene rs3856806 polymorphism and nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2015, 31(7): 1088-1091. doi: 10.3969/j.issn.1001-5256.2015.07.021
[17]	Xin Xuan, Yan HongZhu, Li WeiQing, Yu HongYu. Studies on PPAR α and γ participating in progression of liver fibrosis by regulating ACSL1[J]. Journal of Clinical Hepatology, 2014, 30(7): 700-702. doi: 10.3969/j.issn.1001-5256.2014.07.034
[18]	Xin Xuan, Yan HongZhu, Li WeiQing, Yu HongYu. Studies on PPAR α and γ participating in progression of liver fibrosis by regulating ACSL1[J]. Journal of Clinical Hepatology, 2014, 30(8): 833-835. doi: 10.3969/j.issn.1001-5256.2014.08.038
[19]	Niu TongHong, Zhang Mei, Jiang Man, Xin YongNing, Xuan ShiYing. Research advances in gene polymorphisms in nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2013, 29(12): 947-951. doi: 10.3969/j.issn.1001-5256.2013.12.020
[20]	Shen Bo, Nie YuQiang. Peroxisome proliferator- activated receptor gamma inhibits liver cancer proliferation and metastasis in vitro[J]. Journal of Clinical Hepatology, 2013, 29(9): 702-706. doi: 10.3969/j.issn.1001-5256.2013.09.018

Supplements(0)

Cited By

Cited by

Periodical cited type(7)

1.	季丹. 凝血酶原时间与血小板检测对肝硬化患者诊断的临床意义. 人人健康. 2020(08): 263 .
2.	何搏，张春清. 卡维地洛治疗肝硬化门静脉高压症的作用机制及应用现状. 临床肝胆病杂志. 2019(02): 399-401 . 本站查看
3.	文政伟，李秋兰，何均辉. 慢性乙型肝炎患者抗病毒治疗后肝纤维化动态变化的定性评估. 中国肝脏病杂志(电子版). 2019(01): 77-80 .
4.	曹海丹，黄寅，罗晓蓉，吴县斌. 卡维地洛与普萘洛尔治疗肝硬化门静脉高压的临床疗效及不良反应的对照研究. 北方药学. 2019(11): 138-140 .
5.	高云飞，高凤成，李清峰，马强，邢通潮，杜婷婷. 原发性肝细胞癌患者TACE治疗前后血清血小板源性生长因子-BB水平变化及其临床意义. 现代检验医学杂志. 2019(06): 73-76 .
6.	由淑萍，张石蕾，赵军，马龙，刘涛. 毛蕊花糖苷对血小板衍生生长因子BB处理后大鼠肝星状细胞的影响. 癌变·畸变·突变. 2018(06): 473-478 .
7.	汤伟伟，何永文. PDGF-BB/PDGFR-β与肿瘤发生发展的研究进展. 临床与病理杂志. 2017(11): 2457-2462 .

Other cited types(7)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(1)

Get Citation

PDF

XML

Article Metrics

Article views (607) PDF downloads(117)

Research advances in lean nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2023.12.024